Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The clinicopathological parameters of 36 EOC patients carrying germline BRCA1/2 DM were compared to high-grade serous EOC women of the COEUR cohort with known germline BRCA1/BRCA2 mutation carrier status (n = 376 non-carriers, n = 65 BRCA1 and n = 38 BRCA2).
|
31753525 |
2020 |
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Our findings provide a novel mechanism underlying PARPi resistance in BRCA2 mutated EOC cells, and suggest that inhibition of ALDH1A1 could be exploited for preventing and overcoming PARPi resistance in EOC patients carrying BRCA2 mutation.
|
31534014 |
2020 |
Carcinoma, Ovarian Epithelial
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We searched and evaluated all primary literature on the use of IHC for evaluating BRCA1 and BRCA2 proteins expression in EOC.
|
31719105 |
2020 |
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Comprehensive Profiling of BRCA1 and BRCA2 Variants in Breast and Ovarian Cancer in Chinese Patients.
|
31825140 |
2020 |
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
These genes are associated with an estimated lifetime risk of EOC of 13% to 60% for BRCA1 variants and 10% to 25% for BRCA2 variants, with lower risks associated with remaining genes.
|
31099061 |
2020 |
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In the present study, 21 BRCA1 and BRCA2 pathogenic variants were detected in 30 patients and BRCA1/2 mutations were significantly associated with a family history of breast/ovarian cancer.
|
31706072 |
2020 |
Carcinoma, Ovarian Epithelial
|
0.200 |
Biomarker
|
disease |
BEFREE |
Germline mutations occurring in the highly penetrant genes BRCA1 and BRCA2 are responsible for only certain cases of familial breast cancer (BC) and ovarian cancer (OC).
|
30733081 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Female BRCA1 and BRCA2 mutation carriers have an increased lifetime risk of developing breast and/or ovarian cancer.
|
31370837 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Women who carry a pathogenic mutation in either a BRCA1 DNA repair associated or BRCA2 DNA repair associated (BRCA1 or BRCA2) gene have a high lifetime risk of developing breast and tubo-ovarian cancer.
|
31595976 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations in BRCA1 and BRCA2 genes are the main genetic and inherited factors for breast and ovarian cancer.
|
30552672 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Prevalence, spectrum, and founder effect of BRCA1 and BRCA2 mutations in epithelial ovarian cancer from the Middle East.
|
30825404 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Enzyme-linked immunosorbent assay (ELISA (and Real-time PCR techniques were used to measure the expression level of anti-carcinogenic genes, such as p53, retinoblastoma (RB), breast and ovarian cancer susceptibility gene (BRCA1, BRCA2) and inflammatory cytokines, including tumor necrosis factor α (TNF-α), transforming growth factor β (TGF-β), nuclear factor-kB (NF-kB), and different interleukins [ILs] (IL-1,IL6, and IL-17).
|
30642295 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Testing for variation in BRCA1 and BRCA2 (commonly referred to as BRCA1/2), has emerged as a standard clinical practice and is helping countless women better understand and manage their heritable risk of breast and ovarian cancer.
|
31294896 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the BRCA1 and BRCA2 genes are associated with an increased risk for developing breast and ovarian cancer.
|
30561604 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Individuals carrying pathogenic BRCA1 or BRCA2 mutations have an increased lifetime risk of breast and/or ovarian cancer.
|
30980249 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations of BRCA1 and BRCA2 predispose individuals to a high risk of breast and ovarian cancer, and elevated risk of other cancers, including those of the pancreas and prostate.
|
31464824 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.200 |
Biomarker
|
disease |
BEFREE |
BRCA1 and BRCA2 are the genes related with breast and ovarian cancer.
|
30358186 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations in BRCA1 and/or BRCA2 genes (gBRCA1/2m) are associated with an increased risk of breast cancer (BC) and ovarian cancer (OC).
|
30617925 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Probability of breast/ovarian cancer development is higher in individuals carrying a causative germline DNA variant in BRCA1 or BRCA2 gene responsible for hereditary breast/ovarian cancer (HBOC).
|
29534594 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Women with a BRCA1 or BRCA2 mutation face high risks of breast and ovarian cancer.
|
30971774 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Heterozygous germline mutations in BRCA2 predispose to breast and ovarian cancer.
|
31316060 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Platinum-free interval ≥ 12 months, complete response and normalized CA-125 levels after ultimate platinum-based chemotherapy are associated with prolonged PFS and OS in relapsing BRCA1/BRCA2 mutated ovarian cancer patients who received olaparib as maintenance therapy.
|
31604666 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.200 |
Biomarker
|
disease |
BEFREE |
However, analyses that considered all 41 genes with clinical variables together identified genes TLR4, BSCL2, CDH1, ERBB2, BRCA2 and SCGB2A1 as independently related to survival in OC.
|
31655274 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Deleterious mutations in BRCA1 or BRCA2 genes increase a woman's lifetime risk of breast and ovarian cancer.
|
29863445 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Overall, 178/2192 (8.1%) evaluable OC women showed pathogenic germline mutations in BRCA genes (84 BRCA1;94 BRCA2).
|
31253107 |
2019 |